Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease

Sang Yong Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University School of Medicine, Gwangju, Korea

Nonalcoholic fatty liver disease (NAFLD) is an outstanding example of the complex pathophysiology of the metabolic system and represents both a source and consequence of metabolic syndrome. NAFLD can be seen as the hepatic manifestation of metabolic syndrome and is particularly associated with insulin resistance, obesity, and abnormalities of glucose and lipid metabolism [1]. Furthermore, NAFLD is emerging as a risk factor for diabetes and cardiovascular disease, independently of insulin resistance, metabolic syndrome, plasma lipid level, and other traditional risk factors [2].

NAFLD is defined by evidence of hepatic steatosis, either by imaging or by histology, without any causes for secondary hepatic fat accumulation (e.g., significant alcohol consumption, steatogenic medication, hereditary disorders) [3]. NAFLD is further histologically categorized into nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH), depending on the absence or presence of hepatocellular inflammatory injury with or without fibrosis [3]. The general prevalence of NAFLD in apparently healthy individuals ranges from 3% to 16% in Europe and from 6% to 15% in the United States [4]. Its prevalence is increased in diabetic and obese patients (60% to 80%) and may be as high as 100% in morbidly obese individuals [5]. In a recent cohort study of healthy Korean individuals, NAFLD and its severity were independently and strongly associated with increased incidence of diabetes in men and women, even with euglycemic ranges of glucose and hemoglobin A1c [6].

The gold standard for the diagnosis of NAFLD is liver biopsy, which also differentiates fatty liver from NASH, a critical prognostic determination [7]. However, this procedure is invasive and has a high risk of complication. Therefore, liver biopsy is not adequate as a screening tool for the diagnosis of NAFLD in the general population or in diabetic patients. Some imaging studies such as ultrasonography or computed tomography are an acceptable first-line screening procedure for NAFLD in clinical practice [8]. However, these imaging studies have limitations of relatively low acuity for mild steatosis, low accuracy in morbid obesity, and operator-dependency. For these reasons, numerous noninvasive panels of tests have been developed for the diagnosis of NAFLD consisting of combinations of clinical and routine laboratory parameters, as well as specialized tests [9]. Among them, the fatty liver index (FLI) and the NAFLD fatty liver score were introduced as new noninvasive tools for the diagnosis of NAFLD [10]. Also, adipocyte-specific fatty acid-binding protein (A-FABP), a cytoplasmic protein expressed in macrophages and adipocytes, has been reported as a serum marker involved in metabolic disorders such as metabolic syndrome, type 2 diabetes, and atherosclerosis [11,12]. Although its role and mechanism are not fully elucidated, Milner et al. [13] demonstrated that serum A-FABP levels independently correlate with inflammation and fibrosis of NAFLD in humans.

Jeon et al. [14] investigated the relationship between serum A-
FABP and FLI as indicators of NAFLD in 238 healthy Korean subjects. They reported that the parameters indicating metabolic syndrome such as blood pressure, fasting blood glucose, and lipid panels were significantly higher in the group with FLI ≥30 than in the group with FLI <30 (P<0.001). The baseline serum A-FABP was significantly associated with FLI after adjusting for age and sex (P<0.001), and aspartate aminotransferase, alanine aminotransferase, fasting insulin, total cholesterol, and high density lipoprotein cholesterol were significantly correlated with FLI. Also, a significant association was demonstrated between FLI and ultrasonographic findings of NAFLD. In addition, when subjects were grouped into A-FABP tertiles, the highest tertile of A-FABP had an increased likelihood of FLI ≥30 compared with the lowest tertile (odds ratio, 1.97; P<0.05) [14]. These data were in agreement with other human study which demonstrated that increased serum A-FABP level was a predictive factor for intrahepatic inflammation and fibrosis in patients with histologically confirmed NAFLD with abnormal liver function [13]. Therefore, we can assume that A-FABP with FLI has potential as a predictive marker for the diagnosis of NAFLD. However, to guarantee the role of these noninvasive methods in the diagnosis of NAFLD, several limitations must be overcome. First, a definitive cutoff value of FLI has to be determined for the diagnosis of NAFLD in general populations. Although Bedogni et al. [10] demonstrated that an FLI below 30 rules out fatty liver, while a score greater than 60 indicates fatty liver, these values are suggestive rather than definitive cutoff values. Second, we cannot precisely explain the causal relationship between A-FABP and NAFLD, although several studies have examined the association between A-FABP and fatty liver disease. Although A-FABP plasma level showed a significant progressive increase according to body mass index (BMI) [15], it is not clear whether a high level of A-FABP is a cause of NAFLD or results from a high BMI. Third, subjects in this study were selected from one hospital and are not representative of the general population [14].

Nevertheless, the study is meaningful because it elucidated the relationship between FLI and serum A-FABP as well as other metabolic parameters in healthy Korean subjects. Also, this study suggested these noninvasive markers as potential predictive markers of early diagnosis of NAFLD. Further larger-scale studies are needed to confirm the roles of FLI and A-FABP in NAFLD and obesity. Study for the development of an easy to use method should be ongoing and will be of particular interest.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007;132:2191-207.
2. Chitturi S, Farrell GC. Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health. J Gastroenterol Hepatol 2007;22:967-9.
3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
4. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84.
5. Dixon JB, Bhatnal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121:91-100.
6. Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol. Epub 2013 Oct 8. DOI: 10.1038/ajg.2013.349.
7. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-9.
8. Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, Suh DJ, Kim KM, Bae MH, Lee JY, Lee SG, Yu ES. Noninvasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010;52:579-85.
9. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.
10. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.

11. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007;30:2667-72.

12. Terra X, Quintero Y, Auguet T, Porras JA, Hernandez M, Sabench F, Aguilar C, Luna AM, Del Castillo D, Richard C. FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women. Eur J Endocrinol 2011;164:539-47.

13. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ, George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009;49:1926-34.

14. Jeon WS, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. Association of serum adipocyte-specific fatty acid binding protein with fatty liver index as a predictive indicator of nonalcoholic fatty liver disease. Endocrinol Metab 2013;28:283-7.

15. Queipo-Ortuno MI, Escote X, Ceperuelo-Mallafre V, Garrido-Sanchez L, Miranda M, Clemente-Postigo M, Perez-Perez R, Peral B, Cardona F, Fernandez-Real JM, Tinahones FJ, Vendrell J. FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels. PLoS One 2012;7:e48605.